Aberdeen Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$70.4M Buy
218,624
+3,239
+2% +$1.04M 0.12% 158
2025
Q1
$57.1M Buy
215,385
+24,544
+13% +$6.5M 0.11% 172
2024
Q4
$45.2M Sell
190,841
-9,228
-5% -$2.19M 0.08% 222
2024
Q3
$55M Buy
200,069
+91
+0% +$25K 0.1% 201
2024
Q2
$48.6M Sell
199,978
-19,297
-9% -$4.69M 0.09% 211
2024
Q1
$32.8M Sell
219,275
-13,441
-6% -$2.01M 0.06% 284
2023
Q4
$44.5M Buy
232,716
+209,691
+911% +$40.1M 0.1% 225
2023
Q3
$4.08M Sell
23,025
-559
-2% -$99K 0.01% 596
2023
Q2
$4.48M Buy
23,584
+130
+0.6% +$24.7K 0.01% 594
2023
Q1
$4.7M Buy
23,454
+10,330
+79% +$2.07M 0.01% 582
2022
Q4
$3.12M Buy
13,124
+915
+7% +$217K 0.01% 640
2022
Q3
$2.44M Buy
12,209
+1,408
+13% +$282K 0.01% 672
2022
Q2
$1.58M Sell
10,801
-222
-2% -$32.4K 0.01% 740
2022
Q1
$1.81M Sell
11,023
-144
-1% -$23.6K ﹤0.01% 750
2021
Q4
$1.89M Buy
11,167
+382
+4% +$64.8K ﹤0.01% 784
2021
Q3
$2.04M Buy
10,785
+683
+7% +$129K ﹤0.01% 784
2021
Q2
$1.71M Sell
10,102
-2,043
-17% -$346K ﹤0.01% 798
2021
Q1
$1.72M Buy
12,145
+260
+2% +$36.7K ﹤0.01% 790
2020
Q4
$1.55M Buy
11,885
+159
+1% +$20.7K ﹤0.01% 778
2020
Q3
$1.71M Sell
11,726
-3,016
-20% -$439K ﹤0.01% 730
2020
Q2
$2.18M Buy
14,742
+363
+3% +$53.8K 0.01% 687
2020
Q1
$1.57M Sell
14,379
-142
-1% -$15.5K 0.01% 703
2019
Q4
$1.67M Buy
14,521
+1,126
+8% +$130K ﹤0.01% 746
2019
Q3
$1.08M Buy
13,395
+533
+4% +$42.9K ﹤0.01% 793
2019
Q2
$933K Buy
12,862
+1,276
+11% +$92.6K ﹤0.01% 828
2019
Q1
$1.08M Buy
11,586
+6,793
+142% +$635K ﹤0.01% 801
2018
Q4
$329K Sell
4,793
-50
-1% -$3.43K ﹤0.01% 853
2018
Q3
$424K Sell
4,843
-110
-2% -$9.63K ﹤0.01% 871
2018
Q2
$488K Buy
+4,953
New +$488K ﹤0.01% 855